Brief: Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology
09/02/2026 12:18
Feb 9 (Reuters) - CSL Ltd CSL.AX: MEMO THERAPEUTICS AG ENTERS INTO A COLLABORATION AND OPTION AGREEMENT WITH CSL FOR DEVELOPMENT OF RECOMBINANT POLYCLONAL IGG TECHNOLOGY MEMO THERAPEUTICS AG: AGREEMENT INCLUDES RESEARCH AND DEVELOPMENT FUNDING FOR EXPLORATORY WORK, TECHNOLOGY ACCESS MEMO THERAPEUTICS AG: CO WILL DEVELOP RECOMBINANT POLYCLONAL IGG USING DROPZYLLA PLATFORM TO CLONE ANTIBODY REPERTOIRES,EXPRESS ANTIBODIES Source text: ID:nGNXbydlsF Further company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX